Yusheng Ye

RETRACTION: Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial

Xiaofei Zhu, Yangsen Cao, Wenyu Liu et al. · The Lancet Oncology · 2021 · 72 citations

Medicine, Oncology, Surgery +12

Failure patterns and outcomes of dose escalation of stereotactic body radiotherapy for locally advanced pancreatic cancer: a multicenter cohort study

Xiaofei Zhu, Yangsen Cao, Ting‐Shi Su et al. · Therapeutic Advances in Medical Oncology · 2020 · 23 citations · Full text

Medicine, Oncology, Radiation Oncology +16

Personalized designs of adjuvant radiotherapy for pancreatic cancer based on molecular profiles

Xiaofei Zhu, Yangsen Cao, Xiaoping Ju et al. · Cancer Science · 2020 · 15 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: a secondary analysis of an open-label, randomised, controlled, phase 2 trial

Xiaofei Zhu, Wenyu Liu, Yangsen Cao et al. · EClinicalMedicine · 2022 · 13 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Five-year outcomes of stereotactic body radiation therapy (SBRT) for prostate cancer: the largest experience in China

Xianzhi Zhao, Yusheng Ye, Haiyan Yu et al. · Journal of Cancer Research and Clinical Oncology · 2021 · 12 citations · Full text

Medicine, Oncology, Radiation Oncology +17